COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,237 Articles (22,733 medRxiv, 8,504 bioRxiv)

Most recent first Previous |  Page 1725: Articles 17241-17250  | Next

Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications
Shen, L., Dien Bard, J., Triche, T. J., Judkins, A. R., Biegel, J. A., Gai, X.
10.1101/2021.03.11.434758 — Posted: 2021-03-11
Phodopus roborovskii SH101 as a systemic infection model of SARS-CoV-2
Zhai, C., Wang, M., Chung, H.-J., Hassan, M. M., Lee, S., Kim, H.-J., Hong, S.-T.
10.1101/2021.03.10.434891 — Posted: 2021-03-11
In vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans
Copin, R., Baum, A., Wloga, E., Pascal, K. E., Giordano, S., Fulton, B. O., Zhou, A., Negron, N., Lanza, K., Chan, N., Coppola, A., Chiu, J., Ni, M., Atwal, G. S., Romero Hernandez, A., Saotome, K., Zhou, Y., Franklin, M. C., Hooper, A. T., McCarthy, S., Hamon, S., Hamilton, J. D., Staples, H. M., Alfson, K., Carrion, R., Ali, S., Norton, T., Somersan-Karakaya, S., Sivapalasingam, S., Herman, G. A., Weinreich, D. M., Lipsich, L., Stahl, N., Murphy, A. J., Yancopoulos, G. D., Kyratsous, C. A.
10.1101/2021.03.10.434834 — Posted: 2021-03-11
Low ozone concentration and negative ions for rapid SARS-CoV-2 inactivation
De Forni, D., Poddesu, B., Cugia, G., Gallizia, G., La Licata, M., Lisziewicz, J., Chafouleas, J. G., Lori, F.
10.1101/2021.03.11.434968 — Posted: 2021-03-11
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-CoV-2 Infection in vitro
Gilham, D., Smith, A. L., Fu, L., Moore, D. Y., Muralidharan, A., Reid, S. P. M., Stotz, S. C., Johansson, J. O., Sweeney, M., Wong, N. C., Kulikowski, E., El-Gamal, D.
10.1101/2021.03.10.432949 — Posted: 2021-03-11
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection
Callegaro, A., Borleri, D., Farina, C., Napolitano, G., Valenti, D., Rizzi, M., Maggiolo, F.
10.1101/2021.03.09.21253203 — Posted: 2021-03-11
What level of neutralising antibody protects from COVID-19? .
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., Davenport, M. P.
10.1101/2021.03.09.21252641 — Posted: 2021-03-11
Predicting the Efficacy of COVID-19 Convalescent Plasma Donor Units with the Lumit Dx anti-Receptor Binding Domain Assay.
Janaka, S. K., Clark, N. M., Evans, D. T., Connor, J. P.
10.1101/2021.03.08.21253135 — Posted: 2021-03-11
High-resolution epigenome analysis in nasal samples derived from children with respiratory viral infections reveals striking changes upon SARS-CoV-2 infection
Winkley, K., Koseva, B., Banerjee, D., Cheung, W., Selvarangan, R., Pastinen, T., Grundberg, E.
10.1101/2021.03.09.21253155 — Posted: 2021-03-11
Exploring the short-term role of particulate matter in the COVID-19 outbreak in USA cities
Yoshiaki Kamigauti, L., Martins Palma Perez, G., Souto-Oliveira, C. E., Cowdery, E., Nascimento Saldiva, P. H., Andrade, M. d. F.
10.1101/2021.03.09.21253212 — Posted: 2021-03-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).